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Abstract
Introduction: Docosahexaenoic acid (DHA) and DHA-containing ethanolamine plasmalogens (PlsEtn) are decreased
in the brain, liver and the circulation in Alzheimer’s disease. Decreased supply of plasmalogen precursors to the
brain by the liver, as a result of peroxisomal deficits is a process that probably starts early in the AD disease
process. To overcome this metabolic compromise, we have designed an orally bioavailable DHA-containing ether
lipid precursor of plasmalogens. PPI-1011 is an alkyl-diacyl plasmalogen precursor with palmitic acid at sn-1, DHA at
sn-2 and lipoic acid at sn-3. This study outlines the oral pharmacokinetics of this precursor and its conversion to
PlsEtn and phosphatidylethanolamines (PtdEtn).
Methods: Rabbits were dosed orally with PPI-1011 in hard gelatin capsules for time-course and dose response
studies. Incorporation into PlsEtn and PtdEtn was monitored by LC-MS/MS. Metabolism of released lipoic acid was
monitored by GC-MS. To monitor the metabolic fate of different components of PPI-1011, we labeled the sn-1
palmitic acid, sn-2 DHA and glycerol backbone with
13C and monitored their metabolic fates by LC-MS/MS.
Results: PPI-1011 was not detected in plasma suggesting rapid release of sn-3 lipoic acid via gut lipases. This
conclusion was supported by peak levels of lipoic acid metabolites in the plasma 3 hours after dosing. While PPI-
1011 did not gain access to the plasma, it increased circulating levels of DHA-containing PlsEtn and PtdEtn.
Labeling experiments demonstrated that the PtdEtn increases resulted from increased availability of DHA released
via remodeling at sn-2 of phospholipids derived from PPI-1011. This release of DHA peaked at 6 hrs while increases
in phospholipids peaked at 12 hr. Increases in circulating PlsEtn were more complex. Labeling experiments
demonstrated that increases in the target PlsEtn, 16:0/22:6, consisted of 2 pools. In one pool, the intact precursor
received a sn-3 phosphoethanolamine group and desaturation at sn-1 to generate the target plasmalogen. The
second pool, like the PtdEtn, resulted from increased availability of DHA released during remodeling of sn-2. In the
case of sn-1 18:0 and 18:1 plasmalogens with [
13C3]DHA at sn-2, labeling was the result of increased availability of
[
13C3]DHA from lipid remodeling. Isotope and repeated dosing (2 weeks) experiments also demonstrated that
plasmalogens and/or plasmalogen precursors derived from PPI-1011 are able to cross both the blood-retinal and
blood-brain barriers.
Conclusions: Our data demonstrate that PPI-1011, an ether lipid precursor of plasmalogens is orally bioavailable in
the rabbit, augmenting the circulating levels of unesterified DHA and DHA-containing PlsEtn and PtdEtn. Other
ethanolamine plasmalogens were generated from the precursor via lipid remodeling (de-acylation/re-acylation
reactions at sn-2) and phosphatidylethanolamines were generated via de-alkylation/re-acylation reactions at sn-1.
Repeated oral dosing for 2 weeks with PPI-1011 resulted in dose-dependent increases in circulating DHA and DHA-
containing plasmalogens. These products and/or precursors were also able to cross the blood-retinal and blood-
brain barriers.
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Alzheimer’s disease (AD) is a devastating neurological
disorder characterized by severe cognitive dysfunction.
Diagnosis of AD is not simple and ultimately requires
demonstration of AD pathology, namely the presence of
argyrophilic plaques (amyloid deposition) and neurofi-
brillary degeneration of neurons in the cortex and hip-
pocampus. However, AD pathology is often found in the
brains of older persons with no cognitive impairment
(NCI) [1-3]. These observations raise the question:
“What is the best neuropathological correlate with cog-
nitive decline in AD?” At this time, neuronal/brain atro-
phy [4] and cholinergic dysfunction [5,6] remain
strongly correlated with cognitive decline in AD.
Brain shrinkage in AD is dramatic and is the result
of decrements in myelin volume [7-10] and neuronal
shrinkage that precedes neuronal losses late in the dis-
ease process. The importance of neuronal shrinkage
has been demonstrated for the N. basalis.-cortex choli-
nergic projection [11-14] as well as for neurons in the
amygdala [15] and the neocortex [16,17]. Of interest in
this regard is the recent report that the brains from
individuals with NCI, but a heavy AD pathological bur-
den, suffer from less brain shrinkage than AD patients
[18].
Decreases in critical brain plasmalogen levels for white
and gray matter [19-22] are potentially the basis of these
decreases in brain volume in AD. Since plasmalogens
are essential structural phospholipids of myelin and neu-
rons, decreases in these large phospholipid pools are
probably responsible for hypo-myelination and the
shrinkage of neurons that precedes cell loss. The liver,
which is critical for the supply of plasmalogens and/or
plasmalogen precursors to the brain [23], has decreased
ability to synthesize these precursors in AD presumably,
as a result of peroxisomal dysfunction [24] which has
also been demonstrated in AD brain [25]. This peroxiso-
mal dysfunction is further reflected in decreased circu-
lating levels of plasmalogens in AD [26-28]. In toto,
these data suggest that long-term alterations in plasma-
logen synthesis/degradation result in decreased brain
plasmalogen levels, a hallmark feature of AD.
To correct this metabolic deficiency, we designed a
DHA-containing ether lipid precursor of plasmalogens
that bypasses peroxisomes and has the ability to resup-
ply critical plasmalogen precursors to the brain in AD.
This ether lipid precursor, PPI-1011, can replace plas-
malogens in cell lines and human lymphocytes with per-
oxisomal deficits [28,29] and can augment deficient
circulating and tissue plasmalogens in the mouse cupri-
zone model of demyelination [28]. This report presents
the pharmacokinetic data for this drug after oral dosing
in rabbits.
Materials and methods
Drugs
PPI-1011 is an alkyl-diacyl plasmalogen precursor with
palmitic acid at sn-1, DHA at sn-2 and lipoic acid at sn-
3. The lipoic acid at sn-3 is required to stabilize the pre-
cursor and is rapidly cleaved by gut lipases prior to
addition of the phosphoethanolamine at sn-3 [EC
2.7.8.1] in the gut epithelium and the liver. The final
step in the generation of the 16:0/22:6 plasmalogen is
desaturation of the sn-1 ether linkage [EC 1.14.99.19] in
the endoplasmic reticulum of the gut epithelium and
liver. Remodeling at sn-2 to generate other PtdEtn and
PlsEtn occurs via the sequential actions of lipases
removing the sn-2 fatty acid and acyltransferases repla-
cing an alternate fatty acid. PPI-1038 is PPI-1011 labeled
with [
13C16]palmitic acid, [
13C3]DHA, and [
13C3]glycerol.
PPI-1011 Time Course Study
All rabbit studies were conducted with the University of
Saskatchewan Animal Care Committee approved proto-
col 20080106. Female New Zealand rabbits (1.8-2.5 kg;
Charles River Labs.) were acclimated for 1 week prior to
experimentation. PPI-1011 (200 mg/kg) was dispensed
neat in hard gelatin capsules (size 2; Capsuline Inc.,
Pompano Beach, Fl.) using a pilling gun [30]. For the
time course studies, rabbits were dosed with 200 mg/kg
of PPI-1011 or corn oil and animals sacrificed with
Euthanyl (pentobarbital sodium, 240 mg/ml; 1 ml/2.25
kg iv) at 0, 1, 3, 6, 12, 18, 24 and 48 hr. Blood was col-
lected into tubes containing EDTA by cardiac puncture
and centrifuged at 3500 rcf at 4°C for 10 mins. Plasma
was removed and stored at -70°C for later analysis. Tis-
sues were collected and flash frozen in liquid nitrogen
a n dt h e ns t o r e da t- 7 0 ° C .T issue harvests were con-
ducted as 2 experiments with overlapping groups at 12
hrs (Exp. 1: 1, 3, 6, and 12 hrs; Exp. 2: 12, 18, 24 and 48
hrs). Controls were harvested at each timepoint.
PPI-1038 Time Course Study
A female New Zealand rabbit was acclimated for 1 week
prior to experimentation. PPI-1038 (100 mg/kg orally)
was dispensed neat in a hard gelatin capsule. Serial
blood samples were collected from the ear vein at times
0, 6, 24 and 48 hr. At 48 hr the rabbit was sacrificed
with Euthanyl and tissues collected into TissueTubes
(Covaris) and flash frozen in liquid nitrogen prior to
storage at -70°C.
PPI-1011 Dose Response Study
Six female New Zealand rabbits per group were accli-
mated for 1 week prior to experimentation. PPI-1038 (0,
10, 75, 200, 500 or 1000 mg/kg) was dispensed neat in
hard gelatin capsules. Six hours after dosing, rabbits
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into tubes containing EDTA by cardiac puncture and
plasma stored at -70°C for later analysis.
PPI-1011 Repeated Dosing Study
Six female New Zealand rabbits per group were accli-
mated for 1 week prior to experimentation. PPI-1011 (0,
10, or 50 mg/kg) was dispensed neat in hard gelatin
capsules once daily for 2 weeks. Twenty-four hours after
the last dose rabbits received Euthanyl and terminal
blood collection into tubes containing EDTA by cardiac
puncture and tissue collection were conducted. Tissues
were flash frozen in liquid nitrogen and both tissues and
plasma were stored at -70°C for later analysis.
Tissue Pulverization
Tissue samples in TissueTubes, plastic film-based
pouches with screwtop plugs, were removed from dry
ice and thoroughly frozen in liquid nitrogen before
being placed into the Cryoprep CP02 (Covaris). The
Cryoprep then freeze-fracture pulverized the tissue in <
1s using hammer and anvil technology. After being pul-
verized into a homogenous powder the sample was
placed back in liquid nitrogen. A transfer tube was
directly connected to the TissueTube which upon inver-
sion allowed for easy transfer of the sample into extrac-
tion tubes without thawing.
Plasmalogen Analyses
For plasmalogen analyses, 10 mg of tissue powder in 5
mL screw cap tubes were polytroned in 1 mL of PBS +
0.5 mL MeOH. In the case of plasma, 250 μL were vor-
texed with 1 mL of PBS + 0.5 mL MeOH. Next, 2 mL
tert-butylmethylether were added to the plasma samples
and tissue homogenates and the samples capped and
shaken (1400 rpm) for 15 min at room temperature.
The samples were then centrifuged for 8 min in a clini-
cal centrifuge and 1 ml of the upper organic layer iso-
lated for negative ion electrospray LC-MS/MS analyses
of DHA, ethanolamine plasmalogens and phosphatidy-
lethanolamines as reported previously [26-29]. For the
labeled drug studies, the MRM transitions were adjusted
to monitor the flux of the labeled palmitic acid, DHA
and glycerol backbone. Background values were deter-
mined with time zero samples and subtracted from sub-
sequent timepoints.
Bismethythiohexanoic Acid (BMHA) Analyses
BMHA, the major metabolite of lipoic acid [31] was
quantitated in rabbit plasma. The EDTA plasma (250
μL) was mixed with 1.2 ml of acetonitrile:MeOH:formic
acid (800:200:2.4) containing [
2H3]leucine (CDN Iso-
topes) as internal standard and centrifuged at 4°C and
25,000 × g for 30 min. Next, 400 μL of the supernatant
were dried in a centrifugal evaporator. Alkylation of free
carboxyl and amino groups was performed via heating
at 80°C for 1 hr in 50 uL of pentafluorobenzyl bromide
(5% in dimethylformamide) + 10 uL of diisopropyla-
mine. The samples were next vortexed with 200 uL of
hexane/ethyl acetate (3:2) followed by centrifugation at
25,000 × g and 24°C for 5 min. The clear supernatant
containing the PFBB derivatives were analyzed by GC-
MS with the [M-180]
- anions of 207.1 (BMHA) and
313.2 ([
2H3]leucine) monitored under ammonia NCI.
The GC-MS system was an Agilent 7890A GC and
5975C mass analyzer; the GC column was a 30 m HP-
5MS with 0.25 mm ID and 0.25 μm film.
Data Analyses
Data are presented as mean ± SEM. DHA, PtdEtns &
PlsEtn were normalized to the housekeeping metabolite
PtdEtn 16:0/18:0 while BMHA was expressed as
nmoles/ml plasma. GC-MS analyses were performed
using 5 point standard curves (reference standards at 0.2
to 10 times the stable isotope internal standard). Data
were analyzed by 1-way ANOVA, followed by Dunnett’s
t posthoc analysis to compare treatments to control.
Results
Plasma Time Course (PPI-1011)
First, PPI-1011 was not detected in plasma utilizing the
MRM 815.5 ⇒ 487.3 (i.e. loss of DHA) indicating that
lipase cleavage of lipoic acid at sn-3 occurs as PPI-1011
is absorbed at the gut wall. With an oral dose of 200
mg/kg, a time-dependent increase in the incorporation
of PPI-1011 into circulating plasmalogens was observed
(Figure 1). De-acylation at sn-2 released DHA, with
maximal plasma DHA levels at 6 hours. The greatest
incorporation of PPI-1011 into phospholipids was into
the 16:0/22:6, 18:0/22:6 and 18:1/22:6 ethanolamine
plasmalogens and phosphatidylethanolamines with maxi-
mum incorporation at 12 hours and maintenance of
these levels over the remaining observation period (48
hr; Figure 1).
PPI-1011 also did not alter glycerophosphoethanola-
mine (GPE) plasma levels using the MRM: 214 ⇒ 140
(sn-3 phosphoethanolamine) or 16:0 lysophosphospho-
ethanolamine using the MRM: 436.3 ⇒ 239.2 (sn-1 ether
palmitate). These data support the conclusions that dur-
ing remodeling of phospholipids derived from PPI-1011,
sn-2 is rapidly reacylated following deacylation and that
r e m o v a lo fs n - 1p l u ss n - 2s u b s t i t u e n t sg e n e r a t i n gf r e e
glycerophosphoethanolamine is limited.
Plasma Time Course (PPI-1038)
First, PPI-1038 was not detected in plasma utilizing the
MRM 837.5 ⇒ 506.4 (i.e. loss of [
13C3]DHA) indicating
that lipase cleavage of lipoic acid at sn-3 occurs as PPI-
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also spiked with PPI-1011 and the MRM 815.5 ⇒ 487.3
(i.e. loss of DHA) was clearly monitored in all samples.
With an oral dose of 100 mg/kg, de-acylation of PPI-
1038 at sn-2 released [
13C3]DHA, with plasma [
13C3]
D H Al e v e l sc o n s t i t u t i n g4 0 %o ft h ep l a s m af r e eD H A
pool at 6 hours (Figure 2). The incorporation of [
13C3]
DHA into PtdEtn (16:0/22:6, 18:0/22:6 and 18:1/22:6)
peaked at 24 hr. These data indicate that the increases
in DHA-containing phosphatidylethanolamines observed
with PPI-1011 (Figure 1) dosing are derived from
increased [
13C3]DHA availability and its incorporation
into the sn-2 position of phosphatidylethanolamines.
Incorporation of PPI-1038 into circulating PlsEtn 16:0/
22:6 was equivalent for the fully labeled form ([
13C16]
palmitic acid, [
13C3]DHA, and [
13C3]glycerol) and the
[
13C3]DHA-labeled form (Figure 3). In contrast, PlsEtn
18:0/22:6 and PlsEtn 18:1/22:6 were labeled with [
13C3]
DHA. These data support significant incorporation of
released [
13C3]DHA into PlsEtn 18:0/22:6 and PlsEtn
18:1/22:6 after PPI-1038 dosing.
Analysis of tissue plasmalogens 48 hours after oral
dosing with PPI-1038 (100 mg/kg), demonstrated incor-
poration of the intact plasmalogen precursor into the
target plasmalogen only in the liver (Table 1). Significant
lipid remodeling occurred with both glycerol/DHA-
labeled plasmalogens and DHA-labeled plasmalogens
monitored in the kidney and liver. DHA-labeled plasma-
logens were the major labeled plasmalogens detected in
the brain (Table 1).
Plasma Dose-Response Study (PPI-1011)
Studies of dose-dependent incorporation of PPI-1011
into plasmalogens and phosphatidylethanolamines
demonstrated that a new steady-state level in these cir-
culating phospholipids was attained in a dose-dependent
manner from 10 to 200 mg/kg (Figure 3). However,
further increases in the dose of PPI-1011 up to 1000
mg/kg, did not further increase the steady-state levels of
plasmalogens or phosphatidylethanolamines above that
obtained with the 200 mg/kg dose. In contrast, the high-
est steady-state levels of circulating DHA were obtained
at 500 mg/kg PPI-1011 and did not further increase at a
dose of 1000 mg/kg (Figure 3).
Lipoic Acid Kinetics
Lipoic acid has a short half-life and its major metabolite,
bismethythiohexanoic acid (BMHA) is a more reliable
index of lipoic acid bioavailability. Rabbit plasma BMHA
levels peaked 3 hr after an oral dose of 200 mg/kg, PPI-
Hours
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Figure 1 Time course (1 to 48 hr) of conversion of PPI-1011 to free DHA and DHA-containing plasmalogens (Pls) and
phosphatidylethanolamines (Ptd). Plasma levels are normalized to levels of the housekeeping metabolite PtdEtn 16:0/18:0. The dose of PPI-
1011 was 200 mg/kg, po. N = 3 to 5 except at 12 hours (N = 7). 16:0 (palmitic acid); 18:0 (stearic acid); 18:1 (oleic acid); 22:6 (DHA).
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Page 4 of 10Figure 2 Incorporation of [
13C22]PPI-1038 into plasma DHA-containing ethanolamine plasmalogens (PlsEtn) 6, 24 and 48 hours after
an oral dose of 100 mg/kg in a gelatin capsule. N = 1 rabbit. Figure A, Labeling of PlsEtn 16:0/22:6 (D3, [
13C3]DHA; G3, [
13C3]glycerol; P16,
[
13C16]palmitic acid); Figure B, [
13C3]DHA labeling of PlsEtn 18:0/22:6 and PlsEtn 18:1/22:6.
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Page 5 of 101011 (Figure 4) and declined thereafter. These data sup-
port release of lipoic acid from PPI-1011 prior to sn-2
release of DHA.
Two week Repeated Dosing With PPI-1011
Repeated daily oral dosing for 2 weeks with 10 or 50
mg/kg of PPI-1011 augmented circulating and retinal
ethanolamine plasmalogens in a dose-dependent manner
(Figure 5). This included the target plasmalogen 16:0/
22:6 as well as the 18:0/22:6 and 18:1/22:6 plasmalogens.
Free circulating DHA was also augmented (Figure 5).
Discussion
Decrements in circulating DHA and plasmalogens occur
early in the AD disease process [26-28] and appear to
result from peroxisomal dysfunction in AD liver [24]
and brain [25]. Decrements in liver and circulating
DHA and plasmalogens correlate with decrements in
PPI-1011 (mg/kg, po)
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Figure 3 Dose-response (10 to 1000 mg/kg) for conversion of PPI-1011 to free DHA and DHA-containing plasmalogens (PlsEtn) and
phosphatidylethanolamines (PtdEtn), 6 hours post oral dosing. Plasma levels are normalized to levels of the housekeeping metabolite
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Table 1 Incorporation of stable isotopic label into tissue lipid pools in a rabbit 48 hr after an oral dose of PPI-1038.
Plasmalogen Phosphatidylethanolamine
Lipid Tissue P16-G3-D3 (%) G3-D3 (%) D3 (%) G3-D3 (%) D3 (%)
16:0/22:6 Liver 15.9 5.4 10.5 0 13.2
Kidney 0.1 1.6 18.9 0 14
Brain 0.02 0.15 0.1 0 1
18:0/22:6 Liver - - 17.9 .84 19.8
Kidney - - 22.6 .21 9.6
Brain - - 0.83 0 .57
18:1/22:6 Liver - - 10 20.8 32.9
Kidney - - 22.3 6.5 20.8
Brain - - 3.9 2.9 1.3
Free DHA Liver - - 24.7 - -
Kidney - - 13.6 - -
Brain - - 3.1 - -
P16, [
13C16]palmitate; G3, [
13C3]glycerol; D3, [
13C3]DHA.
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[19-22,24,25]. To correct this plasmalogen deficit we
designed a DHA-containing ether lipid precursor of
plasmalogens that bypasses the requirement for peroxi-
somes. However, plasmalogens and ether lipids in gen-
eral are unstable. In the body, plasmalogens rapidly
associate with chaperone proteins after their synthesis
and are not free in solution until ready for transfer to
membranes. This chemical instability in the ether lipid
PPI-1011 was resolved by the addition of lipoic acid at
sn-3. This substituent protected the molecule from
migration of the sn-2 DHA [32] but was easily cleaved
by gut lipases to generate the alkyl-acyl-glycerol precur-
sor required for the final steps of plasmalogen synthesis
at the level of the endoplasmic reticulum.
PPI-1011 clearly augmented the circulating levels of
the target plasmalogen (PlsEtn 16:0/22:6) in a dose-
dependent and time-dependent manner. Extensive lipid
remodeling occurred at sn-2 where deacylation is
achieved with the 2-acyl hydrolases, phospholipase A2
(EC 3.1.1.4) and acylglycerol lipase (EC 3.1.1.23) and
reacylation via a number of acyl-CoA:lysophospholipid
acyltransferases [33,34] which are tightly coupled to dea-
cylation. Deacylation coupled to reacylation of both
plasmalogens and phosphatidylethanolamines by
released DHA was clearly demonstrated with the stable
isotope labeling study. The efficiency of this process
remains to be evaluated in AD since plasmalogen-selec-
tive phospholipase A2 has been reported to be increased
in AD brain [35].
With respect to supply of plasmalogen precursors to
the brain, redistribution of plasmalogens synthesized by
the gut epithelia [36] and the liver [23,24] is a complex
process in which these lipids are exported from cells via
chaperone proteins like LDL which is a major carrier of
plasmalogens [37]. Tissue uptake of plasmalogens is via a
LDL receptor-mediated transcytosis pathway [38,39]. In
the case of the blood-brain barrier this transport pathway
preferentially transports LDL enriched in DHA-contain-
ing phospholipids [40]. However, depleted levels of brain
DHA, and presumably DHA-containing plasmalogens,
are slowly replaced via supplementation [41]. Our labeled
precursor studies support these prior observations and
suggest that sustained ether lipid precursor dosing will be
required to replete brain plasmalogens.
In summary, our data demonstrate that PPI-1011 is an
orally bioavailable plasmalogen precursor and suggest
that it may offer a new therapeutic approach for treating
AD and other clinical conditions with peroxisomal
dysfunction.
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